Wave Life Sciences Q3 net income $7.3M; initiates first RNA editing clinical program, WVE-006

Wave Life Sciences Ltd.

2023-Q3 EPS reported -$0.39 revenue$84,249,000

Net income of $7.3M vs net loss of $39.0M YoY; revenue increase driven by $48.9M in collaboration milestones.
Cash $139.9M as of Sep 30, plus $7M milestone received in 4Q; runway into 2025.
Initiated RestorAATion clinical program for WVE-006 (RNA editing for AATD); dosing in 4Q 2023, proof-of-mechanism data in 2024.
Enrolled 30mg multi-dose cohort of SELECT-HD for WVE-003; data in 2Q 2024 to enable Takeda opt-in.
Preclinical INHBE siRNA data for obesity; clinical candidate selection in 4Q 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Wave Life Sciences Ltd. reported the third quarter ended September 30, 2023 results: net income Cash and cash equivalents of $140 million as of September 30, 2023.

Period: the third quarter ended September 30, 2023
Net income: Cash and cash equivalents of $140 million as of September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-274068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.